Impact of psychiatric comorbidities in psoriasis, hidradenitis suppurativa and atopic dermatitis: The importance of a psychodermatological approach.
atopic dermatitis
hidradenitis suppurativa
inflammatory skin disease
psoriasis
psychiatric comorbidity
psychodermatological approach
psychological burden
Journal
Experimental dermatology
ISSN: 1600-0625
Titre abrégé: Exp Dermatol
Pays: Denmark
ID NLM: 9301549
Informations de publication
Date de publication:
06 2022
06 2022
Historique:
revised:
18
01
2022
received:
08
07
2021
accepted:
09
03
2022
pubmed:
15
3
2022
medline:
9
6
2022
entrez:
14
3
2022
Statut:
ppublish
Résumé
There is a strong interaction between the immunological and nervous system in the skin. Lesions that are physically disfiguring and chronically relapsing have a high impact on quality of life (QoL) and can result in the emergence of psychiatric disorders. The literature data confirm a higher prevalence of psychiatric disorders in patients with psoriasis, hidradenitis suppurativa (HS) and atopic dermatitis (AD), but such data are compromised by low-quality evidence due to methodological heterogeneity. The primary aim was to analyse the prevalence of psychiatric comorbidities in a group of psoriasis, AD and HS patients compared with a control group. The secondary aims were to evaluate the impact of psychiatric comorbidities on the disease development, severity, flare-ups and QoL. A total of 59 cases and 64 controls were included. Generalized anxiety disorder and depressive disorder with anxious distress were found to be risk factors for AD. Age, smoking and substance-related disorder showed a specific association with HS. Major depressive disorder showed a specific association with dermatology life quality index (DLQI) and all the above disease flare-ups. Atopic dermatitis, psoriasis and HS are associated with psychiatric disorders. A psychodermatological approach improves outcomes in terms of QoL, disease flare-ups and long-term management.
Sections du résumé
BACKGROUND
There is a strong interaction between the immunological and nervous system in the skin. Lesions that are physically disfiguring and chronically relapsing have a high impact on quality of life (QoL) and can result in the emergence of psychiatric disorders. The literature data confirm a higher prevalence of psychiatric disorders in patients with psoriasis, hidradenitis suppurativa (HS) and atopic dermatitis (AD), but such data are compromised by low-quality evidence due to methodological heterogeneity.
OBJECTIVES
The primary aim was to analyse the prevalence of psychiatric comorbidities in a group of psoriasis, AD and HS patients compared with a control group. The secondary aims were to evaluate the impact of psychiatric comorbidities on the disease development, severity, flare-ups and QoL.
METHODS
A total of 59 cases and 64 controls were included.
RESULTS
Generalized anxiety disorder and depressive disorder with anxious distress were found to be risk factors for AD. Age, smoking and substance-related disorder showed a specific association with HS. Major depressive disorder showed a specific association with dermatology life quality index (DLQI) and all the above disease flare-ups.
CONCLUSIONS
Atopic dermatitis, psoriasis and HS are associated with psychiatric disorders. A psychodermatological approach improves outcomes in terms of QoL, disease flare-ups and long-term management.
Identifiants
pubmed: 35285091
doi: 10.1111/exd.14563
pmc: PMC9314578
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
956-961Informations de copyright
© 2022 The Authors. Experimental Dermatology published by John Wiley & Sons Ltd.
Références
Trans St Johns Hosp Dermatol Soc. 1970;56(2):139-42
pubmed: 5516349
J Eur Acad Dermatol Venereol. 2010 Aug;24(8):885-92
pubmed: 20015170
Lancet. 2007 Jul 21;370(9583):263-271
pubmed: 17658397
J Eur Acad Dermatol Venereol. 2000 Jul;14(4):267-71
pubmed: 11204514
Clin Sci (Lond). 2006 Feb;110(2):175-91
pubmed: 16411894
Biol Psychiatry. 2009 May 1;65(9):732-41
pubmed: 19150053
Arch Psychiatr Nurs. 2017 Oct;31(5):516-521
pubmed: 28927517
Arch Dermatol. 2010 Aug;146(8):891-5
pubmed: 20713823
Int J Dermatol. 2012 Jan;51(1):12-26
pubmed: 22182372
J Investig Allergol Clin Immunol. 2009;19 Suppl 1:40-7
pubmed: 19476053
J Eur Acad Dermatol Venereol. 2013 Apr;27(4):473-8
pubmed: 22339940
J Invest Dermatol. 2018 Jan;138(1):46-51
pubmed: 28736236
J Invest Dermatol. 2015 Apr;135(4):984-991
pubmed: 25521458
Med Arch. 2017 Oct;71(5):341-346
pubmed: 29284903
Eur J Dermatol. 2018 Aug 1;28(4):482-487
pubmed: 30325328
Exp Dermatol. 2022 Jun;31(6):956-961
pubmed: 35285091
J Clin Aesthet Dermatol. 2016 Jun;9(6):36-43
pubmed: 27386050
Acta Derm Venereol. 2016 Aug 23;96(217):38-46
pubmed: 27282344
J Am Acad Dermatol. 2018 Sep;79(3):448-456.e30
pubmed: 30119868
Semin Cutan Med Surg. 2017 Jun;36(2):75-78
pubmed: 28538748
Acta Derm Venereol. 2015 Mar;95(3):312-6
pubmed: 24978135
JAAD Case Rep. 2019 Apr 20;5(5):406-409
pubmed: 31049382
JAMA Dermatol. 2019 Aug 01;155(8):939-945
pubmed: 31166590
Medicine (Baltimore). 2015 Jun;94(23):e949
pubmed: 26061325
J Eur Acad Dermatol Venereol. 2015 Feb;29(2):371-376
pubmed: 24909646
Neurosci Biobehav Rev. 1999 May;23(5):699-715
pubmed: 10392661
Allergy. 2018 Jan;73(1):214-220
pubmed: 28632893
J Dtsch Dermatol Ges. 2016 Mar;14(3):233-52; quiz 253
pubmed: 26972185
JAMA Dermatol. 2017 Dec 1;153(12):1263-1269
pubmed: 29117300
Dermatol Ther. 2008 Jan-Feb;21(1):22-31
pubmed: 18318882
Dermatol Ther. 2020 Jul;33(4):e13541
pubmed: 32385861
Curr Med Res Opin. 2021 Aug;37(8):1295-1301
pubmed: 34027753
Int J Dermatol. 1993 Mar;32(3):188-90
pubmed: 8444530